Nautilus Bio (NAUT) Stock Forecast, Price Target & Predictions
NAUT Stock Forecast
Nautilus Bio stock forecast is as follows: an average price target of $6.00 (represents a 106.90% upside from NAUT’s last price of $2.90) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
NAUT Price Target
The average price target for Nautilus Bio (NAUT) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 106.90% upside from NAUT's last price of $2.90.
NAUT Analyst Ratings
According to 3 Wall Street analysts, Nautilus Bio's rating consensus is 'Buy'. The analyst rating breakdown for NAUT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 1 'Hold' (33.33%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Nautilus Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 27, 2024 | Subbu Nambi | Guggenheim | $6.00 | $2.29 | 162.58% | 106.90% |
The latest Nautilus Bio stock forecast, released on Jun 27, 2024 by Subbu Nambi from Guggenheim, set a price target of $6.00, which represents a 162.58% increase from the stock price at the time of the forecast ($2.29), and a 106.90% increase from NAUT last price ($2.90).
Nautilus Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $6.00 | $6.00 |
| Last Closing Price | $2.90 | $2.90 | $2.90 |
| Upside/Downside | -100.00% | 106.90% | 106.90% |
In the current month, the average price target of Nautilus Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Nautilus Bio's last price of $2.90. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 27, 2024 | Guggenheim | - | Buy | Initialise |
| Jun 03, 2024 | Jefferies | - | Hold | Downgrade |
| Apr 26, 2022 | Zacks Investment Research | - | Sell | Downgrade |
Nautilus Bio's last stock rating was published by Guggenheim on Jun 27, 2024. The company Initialise its NAUT rating from "null" to "Buy".
Nautilus Bio Financial Forecast
Nautilus Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $6.60M | $2.05M | $541.67K | $325.00K | $153.25K | $1.83M | $391.67K | $177.00K | - | $166.67K |
| High Forecast | $6.60M | $2.05M | $541.67K | $325.00K | $153.25K | $1.83M | $391.67K | $177.00K | - | $166.67K |
| Low Forecast | $6.60M | $2.05M | $541.67K | $325.00K | $153.25K | $1.83M | $391.67K | $177.00K | - | $166.67K |
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Nautilus Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NAUT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Nautilus Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | - |
| EBITDA | - | - | - | - | - | - | - | - | $-17.02M | $-15.22M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $-18.07M |
| High Forecast | - | - | - | - | - | - | - | - | - | $-14.46M |
| Low Forecast | - | - | - | - | - | - | - | - | - | $-21.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.84% |
undefined analysts predict NAUT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Nautilus Bio's previous annual EBITDA (undefined) of $NaN.
Nautilus Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | - |
| Net Income | - | - | - | - | - | - | - | - | $-17.02M | $-15.50M |
| Avg Forecast | $-26.73M | $-25.48M | $-24.44M | $-23.18M | $-21.93M | $-20.68M | $-20.55M | $-20.36M | $-19.69M | $-18.72M |
| High Forecast | $-26.73M | $-25.48M | $-24.44M | $-23.18M | $-21.93M | $-19.46M | $-20.55M | $-20.36M | $-15.99M | $-14.97M |
| Low Forecast | $-26.73M | $-25.48M | $-24.44M | $-23.18M | $-21.93M | $-20.68M | $-20.55M | $-20.36M | $-23.38M | $-22.46M |
| Surprise % | - | - | - | - | - | - | - | - | 0.86% | 0.83% |
Nautilus Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NAUT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Nautilus Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | - |
| SG&A | - | - | - | - | - | - | - | - | $7.54M | $6.36M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Nautilus Bio's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to NAUT last annual SG&A of $7.54M (Dec 23).
Nautilus Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 2 | 2 | 3 | - |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-0.12 |
| Avg Forecast | $-0.21 | $-0.20 | $-0.20 | $-0.18 | $-0.17 | $-0.17 | $-0.16 | $-0.16 | $-0.16 | $-0.16 |
| High Forecast | $-0.21 | $-0.20 | $-0.20 | $-0.18 | $-0.17 | $-0.16 | $-0.16 | $-0.16 | $-0.13 | $-0.16 |
| Low Forecast | $-0.21 | $-0.20 | $-0.20 | $-0.18 | $-0.17 | $-0.17 | $-0.16 | $-0.16 | $-0.19 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 0.76% |
According to undefined Wall Street analysts, Nautilus Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NAUT previous annual EPS of $NaN (undefined).
Nautilus Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| BCAB | BioAtla | $1.81 | $5.00 | 176.24% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| BEAM | Beam Therapeutics | $26.30 | $64.20 | 144.11% | Buy |
| NAUT | Nautilus Bio | $2.90 | $6.00 | 106.90% | Buy |
| FHTX | Foghorn Therapeutics | $9.72 | $18.00 | 85.19% | Buy |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| DTIL | Precision BioSciences | $10.30 | $15.50 | 50.49% | Buy |
| CRBU | Caribou Biosciences | $2.12 | $3.00 | 41.51% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
NAUT Forecast FAQ
Is Nautilus Bio a good buy?
Yes, according to 3 Wall Street analysts, Nautilus Bio (NAUT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of NAUT's total ratings.
What is NAUT's price target?
Nautilus Bio (NAUT) average price target is $6 with a range of $6 to $6, implying a 106.90% from its last price of $2.9. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Nautilus Bio stock go up soon?
According to Wall Street analysts' prediction for NAUT stock, the company can go up by 106.90% (from the last price of $2.9 to the average price target of $6), up by 106.90% based on the highest stock price target, and up by 106.90% based on the lowest stock price target.
Can Nautilus Bio stock reach $4?
NAUT's average twelve months analyst stock price target of $6 supports the claim that Nautilus Bio can reach $4 in the near future.
What are Nautilus Bio's analysts' financial forecasts?
Nautilus Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.56M (high $2.56M, low $2.56M), average EBITDA is $0 (high $0, low $0), average net income is $-83.524M (high $-82.307M, low $-83.524M), average SG&A $0 (high $0, low $0), and average EPS is $-0.666 (high $-0.657, low $-0.666). NAUT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.52M (high $9.52M, low $9.52M), average EBITDA is $0 (high $0, low $0), average net income is $-99.836M (high $-99.836M, low $-99.836M), average SG&A $0 (high $0, low $0), and average EPS is $-0.797 (high $-0.797, low $-0.797).